MedTrace Logo

The Level of Blood Brain Barrier Damage Biomarker in Acute Ischemic Stroke

NCT05321225 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2022-04-15

No results posted yet for this study

Summary

Hemorrhagic transformation is a common complication of acute ischemic stroke patients . BBB damage is regarded as a major pathophysiological mechanism of hemorrhagic transformation. So, the investigators hypothesis the level of BBB damage biomarker is predictor of intracranial hemorrhage following ischemic stroke.

Conditions

Interventions

DIAGNOSTIC_TEST

the level of biomarker in bood

Elisa is used to test the level of biomarker in blood.

Sponsors & Collaborators

  • Ji Xunming,MD,PhD

    lead OTHER

Principal Investigators

  • Ke Jian Liu, PhD · Xuan Wu Hospital,Capital Medical University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-10
Primary Completion
2023-03-10
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05321225 on ClinicalTrials.gov